BiotechTube
Base4

Base4

San Diego, United States· Est.
base4.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Base4 Biotechnology is a private, preclinical-stage company pioneering a structure-based approach to discover small molecules that target RNA, a challenging but high-potential therapeutic modality. Its core asset is the VERITAS Platform, an AI and quantum biophysics-enhanced platform designed to resolve the dynamic atomic structures of RNA and identify druggable sites. Led by a seasoned team with prior biotech founding and exit success, the company is advancing internal programs while seeking strategic partnerships to accelerate drug development in neurodegenerative diseases, oncology, and rare conditions.

NeurologyOncologyNeuromuscularRare Diseases

Technology Platform

VERITAS Platform: An AI-enhanced, quantum biophysical discovery platform that resolves dynamic atomic-resolution structures of RNA targets to enable structure-based design of selective small molecule modulators.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The opportunity lies in successfully drugging the vast, untapped landscape of disease-causing RNA with small molecules, offering potential best-in-class treatments for neurodegenerative diseases, cancer, and rare genetic disorders.
A validated platform could also generate significant value through multiple lucrative partnerships with large pharmaceutical companies seeking access to this modality.

Risk Factors

Key risks include the high technical difficulty of discovering drug-like small molecules against dynamic RNA targets, the preclinical stage of all programs with no clinical validation, and dependence on future fundraising in a competitive capital environment.
Execution risk in advancing programs to the clinic is significant.

Competitive Landscape

Base4 competes in the emerging field of RNA-targeted small molecules against companies like Arrakis Therapeutics, Skyhawk Therapeutics, and Remix Therapeutics, as well as large pharma initiatives. Competition is based on the robustness of discovery platforms, speed to clinical validation, and intellectual property around both targets and chemical matter.

More companies in Small Molecule Drugs →More companies in United States →